PHASE I DOSE-ESCALATION TRIAL OF MULTIPLE AND FRACTIONATED-DOSE PSMA-TARGETED ALPHA RADIONUCLIDE (225AC-J591) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Sun, Michael
Nauseef, Jones
Fajardo, Andres Ricaurte
Davidson, Zachary
Thomas, Joseph
Ruder, Samuel
Stangl-Kremser, Judith
Castellanos, Sandra Huicochea
Molina, Ana
Sternberg, Cora
Patel, Amie
Yuan, Sarah
Fernandez, Escarleth
Fung, Edward
Avlonitis, Vasilios
O'Dwyer, Elisabeth
Nanus, David
Osborne, Joseph
Bander, Neil
Tagawa, Scott
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
10.1097/01.JU.0001009540.33579.43.11
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD01-11
引用
收藏
页码：E67 / E68
页数：2
相关论文
共 50 条
  • [41] Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer
    Hirofumi Mukai
    Shunji Takahashi
    Masahiro Nozawa
    Yusuke Onozawa
    Jun Miyazaki
    Keiji Ohno
    Kazuhiro Suzuki
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 703 - 710
  • [42] Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Whang, Young E.
    Kaur, Gurveen
    Vallabhajosula, Shankar
    Christos, Paul J.
    Nikolopoulou, Anastasia
    Jhanwar, Yuliya
    Sheikh, Arif
    Ireland, Adam
    Garcias-Espana, Carmen
    Goldsmith, Stanley J.
    Beltran, Himisha
    Bander, Neil Harrison
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC)
    Batra, Jaspreet S.
    Karir, Beerinder S.
    Vallabheiesula, Shenker
    Christos, Paul J.
    Hodes, Gillian
    Date, Pravin R.
    Nikolopoulou, Anastasia
    Jhanwar, Yuliya
    Beltran, Himisha
    Nanus, David M.
    Goldsmith, Stanley J.
    Bander, Nell Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [44] A phase I dose escalation study of PCUR-101 in men with metastatic castration-resistant prostate cancer (mCRPC).
    Kyriakopoulos, Christos
    Paller, Channing Judith
    Verma, Ajit
    Kader, Karim
    Kittrelle, Jeff
    Borgstrom, Per G.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
    Holmes, A.
    Thomas, C.
    Fajardo, A. R.
    Sun, M.
    Castellanos, S. Huicochea
    Nanus, D. M.
    Sternberg, C. N.
    Molina, A. M.
    Yuan, S.
    Avlonitis, V.
    Patel, A.
    Gregos, P.
    Osborne, J.
    Bander, N. H.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S968 - S969
  • [46] Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer
    Vlachostergios, Panagiotis J.
    Niaz, Muhammad Junaid
    Skafida, Myrto
    Mosallaie, Seyed Ali
    Thomas, Charlene
    Christos, Paul J.
    Osborne, Joseph R.
    Molina, Ana M.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    PROSTATE, 2021, 81 (05): : 279 - 285
  • [47] 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
    Sathekge, Mike
    Knoesen, Otto
    Meckel, Marian
    Modiselle, Moshe
    Vorster, Mariza
    Marx, Sebastian
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) : 1099 - 1100
  • [48] 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
    Mike Sathekge
    Otto Knoesen
    Marian Meckel
    Moshe Modiselle
    Mariza Vorster
    Sebastian Marx
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1099 - 1100
  • [49] Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study
    Sui wai Ling
    Astrid A. M. van der Veldt
    Mark Konijnenberg
    Marcel Segbers
    Eline Hooijman
    Frank Bruchertseifer
    Alfred Morgenstern
    Erik de Blois
    Tessa Brabander
    BMC Cancer, 24
  • [50] Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study
    Ling, Sui wai
    van der Veldt, Astrid A. M.
    Konijnenberg, Mark
    Segbers, Marcel
    Hooijman, Eline
    Bruchertseifer, Frank
    Morgenstern, Alfred
    de Blois, Erik
    Brabander, Tessa
    BMC CANCER, 2024, 24 (01)
12345